[KLCC] QoQ Cumulative Quarter Result on 31-Mar-2016 [#1]

Stock
[KLCC] KLCC PROP&REITS-STAPLED SEC
Announcement Date
06-May-2016
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2016
Quarter
31-Mar-2016 [#1]
Profit Trend
QoQ- -83.85%
YoY- 2.38%
Quarter Report
Latest QR
Upcoming QR
KLCC's Result
KLCC's Financial Summary
View:
Show?
Cumulative Result
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
Revenue 1,343,546 998,857 669,322 334,750 1,340,229 993,085 655,900 60.94%
PBT 1,102,698 696,549 466,427 236,100 1,518,355 668,770 463,569 77.72%
Tax -91,671 -78,331 -52,612 -26,698 -115,166 -82,367 -53,302 43.31%
NP 1,011,027 618,218 413,815 209,402 1,403,189 586,403 410,267 81.94%
-
NP to SH 885,971 538,843 360,617 182,754 1,131,521 508,172 358,370 82.33%
-
Tax Rate 8.31% 11.25% 11.28% 11.31% 7.58% 12.32% 11.50% -
Total Cost 332,519 380,639 255,507 125,348 -62,960 406,682 245,633 22.26%
-
Net Worth 12,799,811 12,601,224 12,583,170 12,565,117 12,547,064 12,077,677 12,077,677 3.92%
Dividend
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
Div 643,601 465,775 310,517 155,258 625,547 448,264 301,129 65.54%
Div Payout % 72.64% 86.44% 86.11% 84.95% 55.28% 88.21% 84.03% -
Equity
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
Net Worth 12,799,811 12,601,224 12,583,170 12,565,117 12,547,064 12,077,677 12,077,677 3.92%
NOSH 1,805,333 1,805,333 1,805,333 1,805,333 1,805,333 1,805,333 1,805,333 0.00%
Ratio Analysis
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
NP Margin 75.25% 61.89% 61.83% 62.55% 104.70% 59.05% 62.55% -
ROE 6.92% 4.28% 2.87% 1.45% 9.02% 4.21% 2.97% -
Per Share
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
RPS 74.42 55.33 37.07 18.54 74.24 55.01 36.33 60.94%
EPS 49.08 29.85 19.98 10.12 62.68 28.15 19.85 82.34%
DPS 35.65 25.80 17.20 8.60 34.65 24.83 16.68 65.54%
NAPS 7.09 6.98 6.97 6.96 6.95 6.69 6.69 3.92%
Adjusted Per Share Value based on latest NOSH - 1,805,333
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
RPS 74.42 55.33 37.07 18.54 74.24 55.01 36.33 60.94%
EPS 49.08 29.85 19.98 10.12 62.68 28.15 19.85 82.34%
DPS 35.65 25.80 17.20 8.60 34.65 24.83 16.68 65.54%
NAPS 7.09 6.98 6.97 6.96 6.95 6.69 6.69 3.92%
Price Multiplier on Financial Quarter End Date
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
Date 30/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 -
Price 8.30 7.72 7.48 7.16 7.06 7.00 6.96 -
P/RPS 11.15 13.95 20.18 38.61 9.51 12.73 19.16 -30.18%
P/EPS 16.91 25.86 37.45 70.73 11.26 24.87 35.06 -38.36%
EY 5.91 3.87 2.67 1.41 8.88 4.02 2.85 62.25%
DY 4.30 3.34 2.30 1.20 4.91 3.55 2.40 47.25%
P/NAPS 1.17 1.11 1.07 1.03 1.02 1.05 1.04 8.13%
Price Multiplier on Announcement Date
31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 30/06/15 CAGR
Date 20/01/17 03/11/16 02/08/16 06/05/16 21/01/16 11/11/15 07/08/15 -
Price 7.82 7.80 7.50 7.20 6.96 7.00 7.29 -
P/RPS 10.51 14.10 20.23 38.83 9.38 12.73 20.07 -34.90%
P/EPS 15.93 26.13 37.55 71.13 11.10 24.87 36.72 -42.54%
EY 6.28 3.83 2.66 1.41 9.01 4.02 2.72 74.24%
DY 4.56 3.31 2.29 1.19 4.98 3.55 2.29 57.94%
P/NAPS 1.10 1.12 1.08 1.03 1.00 1.05 1.09 0.60%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment